Scilex (NASDAQ:SCLX) Stock Price Down 8.3% – Here’s Why

Scilex Holding Company (NASDAQ:SCLX – Get Free Report) shares dropped 8.3% on Friday. The company traded as low as $1.4024 and last traded at $1.43. 58,942 shares changed hands during mid-day trading, an increase of 49% from the average daily volume of 39,506 shares. The stock had previously closed at $1.56.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Scilex from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 6th. Weiss Ratings lowered Scilex from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.

Check Out Our Latest Analysis on SCLX

Scilex Stock Performance

The company has a market capitalization of $12.14 million, a P/E ratio of -0.03 and a beta of 1.85. The business has a fifty day moving average of $3.40 and a 200-day moving average of $6.42.

Scilex (NASDAQ:SCLX – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($16.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($16.47). The firm had revenue of $7.64 million for the quarter, compared to analysts’ expectations of $16.00 million.

Institutional Investors Weigh In On Scilex

An institutional investor recently raised its position in Scilex stock. Ashton Thomas Private Wealth LLC raised its position in shares of Scilex Holding Company (NASDAQ:SCLX – Free Report) by 28.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,832 shares of the company’s stock after purchasing an additional 5,350 shares during the period. Ashton Thomas Private Wealth LLC owned 0.28% of Scilex worth $106,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 69.67% of the company’s stock.

About Scilex

(Get Free Report)

Scilex Holding Company (NASDAQ:SCLX) is a pharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. The company’s portfolio is intended to address conditions that may otherwise require opioid-based therapies, with an emphasis on prescription medicines and locally or systemically delivered treatments. Scilex’s commercial products include ZTlido, a prescription lidocaine topical system approved for the treatment of pain associated with postherpetic neuralgia; ELYXYB, an oral solution of celecoxib indicated for the acute treatment of migraine with or without aura in adults; and Gloperba, an oral liquid formulation of colchicine used to treat and prevent gout flares.

Recommended Stories

Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.